the beginning, he had declined an academic offer from Harvard Dental School to accept a research position at Smith, Kline & French Laboratories (SK&F) (Cook, 2010) . But this proved to be a timely choice. At SK&F, he soon discovered the enzyme inhibitor SKF 525A, which became a key tool for the investigation of drug metabolism. More significantly, SKF 525A stimulated Cook's curiosity in a Rhône Poulenc investigational compound, chlorpromazine, also reported to have general drug-potentiating activity. Following the initial intriguing reports of French clinicians and Rhône Poulenc pharmacologist Simone Courvoisier, Cook became the first pharmacologist in the United States to study the unique behavioral properties of chlorpromazine, the drug generally credited for initiating the modern era of psychopharmacology. Cook's conditioned avoidance test data and his strong advocacy played a significant role in SK&F's propitious decision to license and market chlorpromazine (Thorazine) as its first blockbuster drug.
In 1969, Len left SK&F to head the Department of Pharmacology at Hoffmann-La Roche, where he had broad responsibilities for many areas of drug research. An important focus was the Valium-like antianxiety agents, which Cook evaluated with a refined version of the GellerSeifter 'conflict' test (then the gold standard for these agents). Again, but now for a distinctly different drug class, Len was able to show that the relative potency of these agents in a laboratory behavioral assay correlated closely with their anxiolytic potency in patients (Cook and Davidson, 1973) . In 1983, Cook joined DuPont to lead their new pharmaceutical research efforts in the central nervous system. In particular, DuPont's prospective programs in Alzheimer's disease and senility matched well with Cook's long-standing interest in the discovery of novel agents that might improve memorya new class of drugs he termed 'cognitive enhancers'. His group discovered several clinical trial candidates for Alzheimer's disease before his retirement as a Senior Research Fellow of the DuPont Corporation in 1992.
In recognition of these contributions, Len was the recipient of many honors. 
